These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 35280877)

  • 1. A Scoping Review on Use of Drugs Targeting the JAK/STAT Pathway in Psoriasis.
    Gómez-García F; Gómez-Arias PJ; Montilla-López A; Hernández-Parada J; Sanz-Cabanillas JL; Ruano J; Parra-Peralbo E
    Front Med (Lausanne); 2022; 9():754116. PubMed ID: 35280877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis - A network meta-analysis.
    Zhang L; Guo L; Wang L; Jiang X
    J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):1937-1946. PubMed ID: 35608188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata.
    Montilla AM; Gómez-García F; Gómez-Arias PJ; Gay-Mimbrera J; Hernández-Parada J; Isla-Tejera B; Ruano J
    Dermatol Ther (Heidelb); 2019 Dec; 9(4):655-683. PubMed ID: 31606872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors.
    Chimalakonda A; Burke J; Cheng L; Catlett I; Tagen M; Zhao Q; Patel A; Shen J; Girgis IG; Banerjee S; Throup J
    Dermatol Ther (Heidelb); 2021 Oct; 11(5):1763-1776. PubMed ID: 34471993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drugs targeting the JAK/STAT pathway for the treatment of immune-mediated inflammatory skin diseases: protocol for a scoping review.
    Gómez-García F; Gómez-Arias PJ; Hernandez J; Montilla AM; Gay-Mimbrera J; Aguilar-Luque M; Viguera-Guerra I; Velez García-Nieto A; Isla-Tejera B; Ruano J
    BMJ Open; 2019 May; 9(5):e028303. PubMed ID: 31122999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy and safety of JAK/TYK2 inhibitors and other oral drugs for moderate-to-severe plaque psoriasis: Systematic review and network meta-analysis.
    Zheng Y; Han Y; Chen J; Huang J; Zhu C; Lin L; Su H
    Indian J Dermatol Venereol Leprol; 2024; 90(5):590-598. PubMed ID: 38899421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial.
    Papp KA; Bissonnette R; Gooderham M; Feldman SR; Iversen L; Soung J; Draelos Z; Mamolo C; Purohit V; Wang C; Ports WC
    BMC Dermatol; 2016 Oct; 16(1):15. PubMed ID: 27716172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis.
    Roskoski R
    Pharmacol Res; 2023 Mar; 189():106642. PubMed ID: 36754102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral small-molecule tyrosine kinase 2 and phosphodiesterase 4 inhibitors in plaque psoriasis: a network meta-analysis.
    Xu Y; Li Z; Wu S; Guo L; Jiang X
    Front Immunol; 2023; 14():1180170. PubMed ID: 37334353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
    Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
    Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Utility of Deucravacitinib for the Management of Moderate to Severe Plaque Psoriasis.
    Jin JQ; Spencer RK; Reddy V; Bhutani T; Liao W
    Ther Clin Risk Manag; 2023; 19():413-423. PubMed ID: 37223005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Janus Kinase and Tyrosine Kinase Inhibitors in Dermatology: A Review of Their Utilization, Safety Profile and Future Applications.
    Shalabi MMK; Garcia B; Coleman K; Siller A; Miller AC; Tyring SK
    Skin Therapy Lett; 2022 Jan; 27(1):4-9. PubMed ID: 35081305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of tyrosine kinase 2 inhibitor deucravacitinib in the treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.
    Qiu J; Liu J; Liu W; Lin F; Shi N
    Front Med (Lausanne); 2023; 10():1264667. PubMed ID: 37841017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
    Bachelez H; van de Kerkhof PC; Strohal R; Kubanov A; Valenzuela F; Lee JH; Yakusevich V; Chimenti S; Papacharalambous J; Proulx J; Gupta P; Tan H; Tawadrous M; Valdez H; Wolk R;
    Lancet; 2015 Aug; 386(9993):552-61. PubMed ID: 26051365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK-inhibitors in dermatology: current evidence and future applications.
    Ciechanowicz P; Rakowska A; Sikora M; Rudnicka L
    J Dermatolog Treat; 2019 Nov; 30(7):648-658. PubMed ID: 30433838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deucravacitinib: The First FDA-Approved Oral TYK2 Inhibitor for Moderate to Severe Plaque Psoriasis.
    Truong TM; Pathak GN; Singal A; Taranto V; Rao BK
    Ann Pharmacother; 2024 Apr; 58(4):416-427. PubMed ID: 37341177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of Janus kinase inhibitors in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis.
    Yang F; Lu C; Wang Y; Liu H; Leng X; Zeng X
    Clin Rheumatol; 2023 Jun; 42(6):1593-1605. PubMed ID: 36763226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Efficacy and Safety of Peficitinib Versus Tofacitinib and Baricitinib for Treatment of Rheumatoid Arthritis: A Systematic Review and Network Meta-Analysis.
    Tanaka Y; Okumura H; Kim S; Dorey J; Wojciechowski P; Chorąży J; Kato D; Schultz NM
    Rheumatol Ther; 2021 Jun; 8(2):729-750. PubMed ID: 33725321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials.
    Papp KA; Menter MA; Abe M; Elewski B; Feldman SR; Gottlieb AB; Langley R; Luger T; Thaci D; Buonanno M; Gupta P; Proulx J; Lan S; Wolk R;
    Br J Dermatol; 2015 Oct; 173(4):949-61. PubMed ID: 26149717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway.
    Loo WJ; Turchin I; Prajapati VH; Gooderham MJ; Grewal P; Hong CH; Sauder M; Vender RB; Maari C; Papp KA
    J Cutan Med Surg; 2023; 27(1_suppl):3S-24S. PubMed ID: 36519621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.